Retinyl ethers, derivatives and analogues and inhibition of breast carcinogenesis

• US 6,281,250 B1
• Filed: 04/12/1999
• Issued: 08/28/2001
• Est. Priority Date: 04/13/1998
• Status: Active Grant

• Current Assignee: Southwest Research Institute
• Original Assignee: Southwest Research Institute
• Inventors: Shealy, Y. Fulmer
• Primary Examiner(s): Raymond, Richard L.
• Application Number:
  US09/289,748
• Time in Patent Office: 869 Days
• Field of Search: 568/329, 568/631, 568/646, 568/640, 568/659, 568/660, 568/661, 514/683, 514/717
• US Class Current: 514/683
• CPC Class Codes: C07C 2601/16 the ring being unsaturated
• CPC Class Codes: C07C 403/02 having side-chains containing only carbon and hydrogen atoms
• CPC Class Codes: C07C 403/08 by hydroxy groups
• CPC Class Codes: C07C 403/10 by etherified hydroxy groups
• CPC Class Codes: C07C 43/166 having unsaturation outside the aromatic rings

Abstract

The present invention is directed to retinyl ethers, derivatives and analogues and their use in inhibiting breast carcinogenesis or breast cancer cell growth.

Claims

1. A compound having the general formula

2. The compound of claim 1 wherein X is structure (a).

3. The compound of claim 1 wherein X is structure (b).

4. The compound of claim 1 wherein X is structure (c).

5. The compound of claim 1 wherein Y is unsubstituted or substituted aryl.

6. The compound of claim 5 wherein the aryl is phenyl.

7. The compound of claim 5 wherein the aryl is naphthyl.

8. A method of inhibiting breast cancer in an individual which comprises administering to the individual an effective amount of a compound having the general formula

9. The method of claim 8 wherein X is structure (a).

10. The method of claim 8 wherein X is structure (b).

11. The method of claim 8 wherein X is structure (c).

12. The method of claim 8 wherein Y is unsubstituted or substituted aryl.

13. The method of claim 12 wherein the aryl is phenyl.

14. The method of claim 12 wherein the aryl is naphthyl.

15. The method of claim 8 wherein a second antineoplastic agent is further administered to said individual.

16. The method of claim 8 wherein said effective amount is in the range from about 0.1 mg/kg/day to about 1,000 mg/kg/day.